Base by Base

Base by Base explores advances in genetics and genomics, with a focus on gene-disease associations, variant interpretation, protein structure, and insights from exome and genome sequencing. Each episode breaks down key studies and their clinical relevance—one base at a time.Powered by AI, Base by Base offers a new way to learn on the go. Special thanks to authors who publish under CC BY 4.0, making open-access science faster to share and easier to explore.

Base by Base is a science podcast hosted by Gustavo Barra, with 460 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Gustavo Barra hosts Base by Base, a science show with 460 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #459

  459: Cerebral palsy genetics: 515 candidate genes, evidence for 89

  Sep 13, 202624 minS2

  Arterbery et al., The American Journal of Human Genetics - Hundreds of genes have been reported as causes of cerebral palsy, yet there is no agreed model of what a pathogenic variant in a child with CP actually means. This study treats CP as a phenotypic feature that some genetic disorders make more likely, tests the reported genes against the population prevalence of CP across tens of thousands of published individuals, and finds statistical evidence of association for only 89 of 515, before applying that stratification to genome sequencing of 460 children with CP. Key terms: cerebral palsy, Mendelian disease, genome sequencing, Human Phenotype Ontology, gene-disease association. Study Highlights: Across 21 published genomic diagnostic cohorts, variants deemed causal of cerebral palsy had been reported in 515 genes, with no consensus on whether such variants cause CP, mimic it, or coexist with it. The authors modelled CP as a phenotypic feature with a known population prevalence and applied a Bonferroni-corrected binomial test to 280 genes drawn from 5,508 publications describing 43,897 individuals, rejecting the null hypothesis of no association for 86 genes, and for 89 when combined with the genes enriched across the CP sequencing cohorts. Genome sequencing of 460 children with CP from 453 families at Shriners Children's identified pathogenic or likely pathogenic variants in 60 genes in 15.8% of the children. Only 16 of those 60 genes had significant literature evidence for CP association, which still represented a 16.3-fold enrichment over the overlap expected by chance. The results support a stratified approach in which the strength of evidence for each gene shapes how a molecular finding in a child with CP is interpreted. Conclusion: A pathogenic variant found in a child with cerebral palsy does not carry the same weight for every gene: for most of the 515 genes reported so far, the literature does not yet provide statistical evidence that the associated disorder raises the likelihood of CP. Treating CP as a phenotype with graded genetic evidence offers a framework for attributing causality more carefully in precision genomic diagnosis, while leaving open that more genes may prove to be associated as data accumulate. Music: Enjoy the music based on this article at the end of the episode. Article title: A phenotypic paradigm for cerebral palsy genetics First author: Arterbery Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.08.007 Reference: Arterbery, A.S., Gargano, M.A., et al., and Robinson, P.N. (2026). A phenotypic paradigm for cerebral palsy genetics. The American Journal of Human Genetics 113, 1972-1986. https://doi.org/10.1016/j.ajhg.2026.08.007 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/cerebral-palsy-genetics-phenotypic-model QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-09-13. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, intro/outro, and music

  ListenShow Notes
• 

  Episode #458

  458: Somatic or inherited? Reading TP53 risk from shared DNA

  Sep 10, 202625 minS2

  MacGregor et al., The American Journal of Human Genetics - Pathogenic TP53 variants found in blood have long been read as inherited Li-Fraumeni alleles, but many turn out to be somatic clones that grew with age. Using whole-exome data from 469,391 UK Biobank participants, this study combines variant allele fraction with haplotype sharing to tell the two origins apart, and finds that in cancer-free middle-aged adults the risk is mostly somatic and mostly hematological. Key terms: TP53, clonal hematopoiesis, Li-Fraumeni syndrome, UK Biobank, variant classification. Study Highlights: Rare coding TP53 variants were called in 469,391 UK Biobank participants aged 40 to 70, and 1,753 nonsynonymous variants were sorted by variant allele fraction combined with haplotype sharing across individuals carrying the same allele. Of 55 unique pathogenic TP53 variants detected, only six were classified as germline, and most of those sit at positions linked to partial rather than complete loss of p53 function. Classic Li-Fraumeni alleles behaved like somatic clonal expansions: their prevalence rose with age at an odds ratio of 2.3 per decade, while likely germline variants showed no age trend. Incident cancer risk separated sharply by origin, with the signal for somatic and inconclusive variants driven almost entirely by blood cancers rather than solid tumors, reaching a hazard ratio of 16.5 for the high-allele-fraction inconclusive class. The prevalence of somatic expansion tracked missense pathogenicity, suggesting that clonal growth in blood is itself an in vivo readout of how much a variant damages p53. Conclusion: In a population cohort of healthy middle-aged adults, most apparently pathogenic TP53 variants detected in blood reflect somatic clonal expansion rather than inherited predisposition, and the cancer risk they carry is predominantly hematological. Distinguishing the two origins with allele fraction and shared haplotypes gives a scalable way to interpret TP53 variants outside the clinic, where classic Li-Fraumeni assumptions do not hold. Music: Enjoy the music based on this article at the end of the episode. Article title: Shared inheritance reveals landscape of somatic and germline cancer risk in TP53 First author: MacGregor Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.07.011 Reference: MacGregor, H.A.J., Blundell, J.R., and Easton, D.F. (2026). Shared inheritance reveals landscape of somatic and germline cancer risk in TP53. The American Journal of Human Genetics 113, 1916-1928. https://doi.org/10.1016/j.ajhg.2026.07.011 License: This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Support: Base by Base is independent and ad-free — no sponsors, no paywall. If an episode was worth your time, chip in and keep the papers audited and the original songs coming: ❤️ Support monthly: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ One-time donation: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 ▶️ Watch with chapters on YouTube: https://www.youtube.com/@basebybase More at basebybase.com On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/tp53-somatic-germline-cancer-risk-biobank QC: This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-09-10. QC Scope: - article metadata and core scientific claims from the narration - excludes analogies, intro/outro, and music - transcript coverage: Audited the scientific body from the TP53 and Li-Fraumeni background through clonal hematopoiesis, the allele-f...

  ListenShow Notes
• 

  Episode #457

  457: A deletion that raises Alzheimer risk, a duplication that lowers it

  Sep 9, 202624 minS2

  Quenez O et al., The American Journal of Human Genetics - Rare copy-number variants were called from 22,319 exomes covering early-onset Alzheimer disease, late-onset disease and unaffected controls, then tested gene by gene for a dosage effect. One locus came back with the cleanest signal in the field: at the central 22q11.21 region, deletions appeared only in early-onset cases, including one that arose de novo, while duplications piled up in controls, with late-onset cases sitting in between. Replication in nearly 400,000 further individuals confirmed it, and overexpressing SCARF2, one of the genes in the narrowed interval, increased amyloid-beta uptake in cells - the direction the protective duplications would predict. Key terms: copy-number variants, Alzheimer disease, 22q11.21, SCARF2, gene dosage. Study Highlights: The authors called rare copy-number variants from 22,319 harmonized exomes, comprising 4,150 early-onset Alzheimer cases at 65 years or younger, 8,519 late-onset cases and 9,650 unaffected controls, and found that early-onset cases carried an excess burden of rare CNVs affecting coding genes, driven particularly by deletions in genes already implicated in the disease. Pooling short truncating variants with deletions into a single loss-of-function analysis implicated ABCA1 with an odds ratio of 5.77 and ABCA7 deletions with an odds ratio of 2.29, and raised CTSB as a new candidate at an odds ratio of 5.03. An exome-wide gene-level dosage analysis then flagged 18 genes across five loci below a 10 percent false discovery rate, of which the central 22q11.21 region stood out: deletions were restricted to early-onset cases and absent from all 9,559 controls, duplications were enriched in controls, and late-onset cases fell in between, a gradient the authors narrowed to the SCARF2-KLHL22-MED15 interval. Replication across 33,977 additional cases and 362,322 controls confirmed the association at exome-wide significance, with duplications carrying an odds ratio of 0.34 and a mega-analysis p value of 5.52 times ten to the minus seven. Transfecting SCARF2 into microglial cells significantly increased uptake of fluorescent amyloid-beta with a p value of 2.2 times ten to the minus five, while uptake of inert latex beads did not change, arguing the effect is specific rather than a general boost in cell appetite. Conclusion: The same stretch of chromosome 22 pushes Alzheimer risk in opposite directions depending on how many copies you carry: losing one raises risk, gaining one lowers it. Duplications of the central 22q11.21 region emerge as one of the strongest risk-decreasing genetic factors described so far in terms of effect size, behind only the ultra-rare Icelandic APP variant, and unlike that variant they are found across multiple ancestries. The authors are careful about what this does not mean: the deletions are extremely rare, protection is relative rather than absolute, and they show it directly by pointing to duplication carriers who developed late-onset disease anyway while carrying other risk factors. Power is the central constraint, because each genome carries hundreds of rare coding point variants but typically only one rare coding CNV, and the analysis was restricted to individuals of European ancestry. Music: Enjoy the music based on this article at the end of the episode. Article title: Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk First author: Quenez O Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.07.013 Reference: Quenez O, Schramm C, Cassinari K, Nicolas A, Groeneveld J, Huguet G, et al. Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk. The American Journal of Human Genetics. 2026;113(10):1-19. doi:10.1016/j.ajhg.2026.07.013 Li...

  ListenShow Notes
• 

  Episode #456

  456: Beyond exons: where heritability hides as traits get more polygenic

  Sep 8, 202646 minS2

  Fuhrer J et al., The American Journal of Human Genetics - Across 34 complex traits and disorders, a MiXeR-based framework partitions SNP heritability over 74 functional annotations and finds that exons carry only a minority of it, and steadily less as a trait becomes more polygenic. Exonic heritability falls from about 22 percent in less-polygenic somatic diseases and biomarkers to about 13 percent in highly polygenic psychiatric and cognitive traits, intergenic heritability rises by the same logic, and intronic heritability stays put. A new annotation contribution score shows the same axis in the annotations themselves: highly polygenic traits load on conservation and variant-effect scores, less-polygenic traits on promoter, transcription and chromatin marks. Key terms: polygenicity, SNP heritability, noncoding variation, functional annotation, complex traits. Study Highlights: The authors extended the MiXeR framework to model SNP effect-size variance across 74 binary functional annotations, applied it to 34 traits spanning psychiatric, neurological, cardiometabolic, anthropometric, hematological and immune phenotypes, and introduced a likelihood-based annotation contribution score that measures how much a single annotation adds to the full model rather than how enriched it is per SNP. Exons cover 2.55 percent of base pairs and account for a mean of 14.52 percent of heritability, with introns and intergenic regions together explaining the remaining 85.49 percent; introns alone typically carry about half. Regressing regional fractions on log polygenicity, the exonic fraction falls 4.38 percentage points and the intergenic fraction rises 4.87 percentage points per ten-fold increase in polygenicity, while the intronic slope is not significant, and the illustrative spread runs from 8.51 percent exonic in schizophrenia to 29.44 percent in sex-hormone-binding globulin. The contribution score peaks for mid-sized annotations covering roughly 10 to 15 percent of SNPs, so compact conservation tracks such as phastCons, GERP, CADD and Eigen dominate in highly polygenic traits while promoter and chromatin tracks such as H3K4me3 and CpG islands dominate in less-polygenic ones. Sensitivity analyses against sLDSC and sLD4M agreed closely, with heritability fractions correlating at r equals 0.996 and polygenicity estimates at Spearman r equals 0.91. Conclusion: The functional location of heritability is not a fixed property of the genome but tracks a trait's polygenicity: less-polygenic somatic traits concentrate heritability in coding and gene-proximal regulatory regions, while highly polygenic psychiatric and cognitive traits distribute it across dispersed distal regulatory elements. Because enrichment per SNP and total contribution can point in opposite directions, the authors argue both must be read together, and they note that coding variants explain a minority of heritability throughout, which argues for sequencing designs that maximize noncoding coverage. The analysis relies on European-ancestry reference panels, uses relatively broad annotations with incomplete chromosome X coverage, and depends on polygenicity estimates from two methods that nonetheless agreed closely. Music: Enjoy the music based on this article at the end of the episode. Article title: Beyond exons: Linking noncoding heritability and polygenicity across complex human traits and disorders First author: Fuhrer J Journal: The American Journal of Human Genetics DOI: 10.1016/j.ajhg.2026.08.012 Reference: Fuhrer J, Shadrin AA, Hughes T, Parker N, Hindley G, Frei E, Nguyen D, Smeland OB, Djurovic S, Andreassen OA, Dale AM, Frei O. Beyond exons: Linking noncoding heritability and polygenicity across complex human traits and disorders. The American Journal of Human Genetics. 2026;113(10):1-13. doi:10.1016/j.ajhg.2026.08.012 License: This episode is based...

  ListenShow Notes
• 

  Episode #454

  454: Efavirenz retarda a doença priônica mexendo no colesterol do cérebro [PT]

  Sep 2, 202617 minS2

  Ali T et al., JCI Insight - Um antirretroviral aprovado para HIV, dado por via oral em microdose, prolongou a sobrevida de camundongos que carregam a proteína priônica humana e foram infectados com príons de doença de Creutzfeldt-Jakob esporádica humana. O efavirenz age ativando a CYP46A1, a enzima cerebral que converte colesterol numa forma capaz de sair do cérebro — e não baixando a proteína priônica, como as abordagens dos episódios anteriores desta série. Termos-chave: efavirenz, CYP46A1, doença de Creutzfeldt-Jakob, metabolismo do colesterol cerebral, reposicionamento de medicamento. ⚠️ Importante: nada neste episódio é motivo para tomar efavirenz. O efavirenz é um antirretroviral de prescrição com efeitos colaterais reais, incluindo distúrbio do sono, sonhos vívidos, tontura e efeitos psiquiátricos. A dose usada neste estudo — cerca de 0,09 mg/kg por dia — é algo entre 300 e 400 vezes menor que a dose prescrita para HIV, e não é algo que alguém consiga aproximar por conta própria. Nenhum ser humano teve benefício demonstrado com efavirenz para doença priônica. Existe um ensaio de Fase 3 registrado como NCT07482085 no ClinicalTrials.gov, que ainda não reportou resultados. Se a doença priônica afeta você ou sua família, converse com um neurologista e pergunte sobre ensaios registrados — não sobre a farmácia. Este é o quarto episódio da nossa série sobre a doença de Creutzfeldt-Jakob, que começou como homenagem ao Lito Sousa. Todos os ensaios citados na série estão registrados publicamente no ClinicalTrials.gov. Destaques do estudo: Os autores inocularam camundongos tg650, que superexpressam a PrP humana, com príons MM1 de CJD esporádica humana e começaram o efavirenz oral em dose baixa aos 30 ou aos 130 dias após a infecção, prolongando a sobrevida em 17 e 23 dias respectivamente. Na fase clínica inicial, os animais tratados apresentaram menos PrPSc, menor teor de colesterol e de gotículas lipídicas no cérebro, e níveis mais altos de CYP46A1 e de 24S-hidroxicolesterol no cérebro e no soro. Superexpressar a CYP46A1 sozinha em células neuronais infectadas já reduziu a PrPSc e elevou o 24S-hidroxicolesterol, ligando o efeito antipriônico à enzima e não a outra propriedade do remédio. A dose usada foi de cerca de 0,09 mg/kg por dia, algo entre 300 e 400 vezes menor que a dose padrão prescrita para HIV. A eficácia no início tardio importa clinicamente, porque o paciente chega depois que os sintomas começaram. Conclusão: O efavirenz oral em dose baixa ativa a CYP46A1, restaura a renovação de colesterol no cérebro, reduz o acúmulo de PrPSc e prolonga a sobrevida num modelo humanizado de CJD esporádica, o que sustenta avaliar melhor esse medicamento reposicionado em doença priônica humana. Música: Ouça a música criada a partir deste artigo no final do episódio. Título do artigo: Treatment with efavirenz extends survival in a Creutzfeldt-Jakob disease model by regulating brain cholesterol metabolism Primeiro autor: Ali T Revista: JCI Insight DOI: 10.1172/jci.insight.190296 Referência: Ali T, Cashion J, Hannaoui S, Ahmed-Hassan H, Schatzl H, Gilch S. Treatment with efavirenz extends survival in a Creutzfeldt-Jakob disease model by regulating brain cholesterol metabolism. JCI Insight. 2025;10(14):e190296. doi:10.1172/jci.insight.190296 Licença: Este episódio é baseado em um artigo de acesso aberto publicado sob a Licença Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/ Apoie: O Base by Base é independente e sem anúncios — sem patrocinadores, sem paywall. Se o episódio valeu o seu tempo, contribua e ajude a manter os artigos auditados e as músicas originais: ❤️ Apoio mensal: https://buy.stripe.com/cNifZhclVebvagk2JDgEg01 ☕ Doação única: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 Mais em basebybase.com

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.